HDAC9 and acute myeloid leukemia: A post hoc analysis of the Medical research Council (MRC) AML15 randomized trial showed that patients with CBF AML who completed two courses of FLAG and idarubicin (FLAG-IDA) followed by 2 courses of HDAC had the best long term survival [25, 27].